[The clinical efficacy and outlook for the use of new drugs for metabolic therapy in dermatology].
Based on the literature data and their own findings, the authors give grounds for the use of phosphaden, riboxin, and dipromonium in psoriasis, eczema, and atrophic lichen. Prospects in the application of vitamin synthetic analogues and of coenzymic preparations are shown.